RaQualia Pharma
Nagoya
About RaQualia Pharma
RaQualia began operations in July 2008 with a corporate mission, "They seek to bring people health and happiness through innovative new medications." Thanks to the support of all of their stakeholders, the company was listed on the JASDAQ Growth Market in July 2011. They have transformed RaQualia's R&D strategy, which is now based on the concept of "selection and concentration." They are now focusing on their core competencies in targeting ion channels in the fields of pain and gastrointestinal disease. In addition, they have made a strategic decision to relocate RaQualia's discovery processes to Nagoya University to better promote synergy effects with academia. With the Chubu region as their base, they are continuing with further efforts enhance their capabilities in drug discovery, improve shareholder value, and achieve financial stability by promoting licensing activities and alliance management with their corporate partners. They will continue to work tirelessly in providing patients with innovative medicines sooner by increasing the pace of drug development. Thank you very much for your continued support of RaQualia.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Funding stage: IPO
- Last round: Series Unknown (Jul 2008)
- Ticker: tyo:4579
- Website: raqualia.com
Industries & Categories
Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/raqualia-pharma-1608014 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.